compounded semaglutide crackdown news november 2025 FDA restricts non-approved GLP-1 weight loss products FDA proposes a new GLP-1

Use of this information is at your own risk, and we are not liable for any outcomes resulting from its use.

Cold-Chain Shipping Standards Good Two thin ice packs inside the branded water bottle

It is FDAapproved at specific doses and brand names for type 2 diabetes and chronic weight management in defined populations when combined with lifestyle interventions

This can help reduce daily calorie intake and make it easier to stick to a healthy eating plan

Severe side effects of the medication are: Severe gastrointestinal problems Low blood sugar levels (hypoglycemia) Changes in vision due to diabetic retinopathy pancreatitis Gallbladder problems Hypoglycemia Allergic reaction to the medication Severe stomach pain Risk of aspiration during sedation or anesthesia Mood and behavioural changes Suicidal ideation Limitations Semaglutide is contraindicated for patients with a history or family history of thyroid cell tumors (MTC) and endocrine cancers (MEN 2 syndrome) because the medication increases the risk of these tumors in rodent studies

Key Takeaways No Clinical Data Exists (as of 2026): There are currently no published clinical studies or peer-reviewed research specifically examining the safety or efficacy of combining MOTS-c with Retatrutide in human subjects